arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TScan Therapeutics, Inc.

TCRX
$0.18 ▼ -0.03 (-13.12%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

TScan Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $23.4M
Dividend Yield —
Revenue Growth -65.8% ↘
Op. Margin None
ROIC -23.7% ↘
FCF / Share $-0.22 ↘
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity 0.47
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.05M
↓ -65.8% —
Net Income Profit after all expenses
$-30.36M
↑ +17.8% —
Operating Margin Operating profit as % of sales
-296.2%
↑ +11.4% —
FCF / Share Free cash flow per share
$-0.22
↑ +19.0% —
Long-Term Debt Long-term obligations
$32.78M
— +0.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
8
Financial Health →
42
Cash Quality ↓
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 27 quarters